Special Issue "Metabolic Syndrome and Cardiovascular Disease"
Deadline for manuscript submissions: closed (30 July 2023) | Viewed by 4264
Metabolic syndrome is defined as the concurrence of at least three of the following metabolic risk factors:
- Atherogenic dyslipidemia (elevated serum levels of triglycerides, or low levels of high-density lipoprotein (HDL) cholesterol);
- Elevated blood pressure;
- Elevated glucose levels (insulin resistance and/or impaired glucose tolerance);
- Abdominal obesity expressed by increased waist circumference.
Early diagnosis and management, both pharmacological and nutritional, of the metabolic syndrome are crucial for public health in modern societies, as each component thereof is an independent risk factor for cardiovascular disease (CVD). The combination of these risk factors elevates the prevalence and severity of a spectrum of cardiovascular conditions, including microvascular dysfunction, coronary atherosclerosis and calcification, cardiac dysfunction, myocardial infarction, and heart failure.
The plethora of mechanisms and modes of action implicated in the cardiovascular complications of metabolic syndrome are not yet fully elucidated, and remain incompletely understood. A causal relationship between insulin resistance and other metabolic risk factors is less certain. The prothrombotic state induced by abdominal obesity promotes the development of atherosclerosis or participates in the development of acute atherosclerotic CVD events. Perhaps the most attractive candidate for enhanced atherogenicity associated with coagulation and fibrinolytic abnormalities is endothelial dysfunction.
In this Special Issue, we intend to highlight current knowledge regarding the pathophysiologic consequences of the metabolic syndrome on cardiovascular function and disease, including considerations of potential physiologic and molecular mechanisms that may contribute to these adverse outcomes. In addition, interventions to minimize the adverse effects of metabolic syndrome risk factors on the cardiovascular system will also be discussed.
Dr. Konstantinos Tsarouhas
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- insulin resistance
- endothelial dysfunction
- prothrombotic state